• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Tresiba (insulin degludec injection)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Tresiba (insulin degludec injection)

  • Profile

Profile

Contact Information

Contact: Novo Nordisk
Website: https://www.novomedlink.com/diabetes/products/treatments/tresiba.html

Currently Enrolling Trials

    Show More

    General Information

    Tresiba (insulin degludec) is a long-acting human insulin analog.

    Tresiba is specifically indicated to improve glycemic control in adults with diabetes mellitus. 

    Mechanism of Action

    The primary activity of insulin, including Tresiba, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis. Tresiba forms multi-hexamers when injected into the subcutaneous tissue resulting in a subcutaneous insulin degludec depot. The protracted time action profile of Tresiba is predominantly due to delayed absorption of insulin degludec from the subcutaneous tissue to the systemic circulation and to a lesser extent due to binding of insulin degludec to circulating albumin.

    Side Effects

    Adverse effects associated with the use of Tresiba may include, but are not limited to, the following:

    • hypoglycemia
    • allergic reactions
    • injection site reactions
    • lipodystrophy
    • pruritus
    • rash
    • edema
    • weight gain

    Dosing/Administration

    Tresiba is supplied as an injection for subcutaneous administration. Inject Tresiba subcutaneously once daily at any time of day into the thigh, upper arm or abdomen. Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy. Individualize and titrate the dose of Tresiba based on the patient’s metabolic needs, blood glucose monitoring results and glycemic control goal. The recommended days between dose increases is three to four days. The recommended doses are as follows:

    Starting dose in insulin-naïve patients:

    Type 1 diabetes mellitus: The recommended starting dose of Tresiba in insulin-naïve patients with type 1 diabetes is approximately one-third to one-half of the total daily insulin dose. The remainder of the total daily insulin dose should be administered as a short-acting insulin and divided between each daily meal. As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin naïve patients with type 1 diabetes. Type 2 diabetes mellitus: The recommended starting dose of Tresiba in insulin-naïve patients with type 2 diabetes mellitus is 10 units once daily.

    Starting dose in patients already on insulin therapy:

    Type 1 and type 2 diabetes mellitus: Start Tresiba at the same unit dose as the total daily long- or intermediate-acting insulin unit dose. 

    Clinical Trial Results

    The FDA approval of Tresiba was based on the following trials:

    Type 1 Diabetes

    Tresiba administered at the same time each day in combination with a rapid-acting insulin analog at mealtimes:

    Study A:

    The efficacy of Tresiba was evaluated in a 52-week randomized, open-label, multicenter trial in 629 patients with type 1 diabetes mellitus. Patients were randomized to Tresiba once-daily with the evening meal or insulin glargine U-100 once-daily according to the approved labeling. Insulin aspart was administered before each meal in both treatment arms. At week 52, the difference in HbA1c reduction from baseline between Tresiba and insulin glargine U-100 was -0.01 percent with a 95 percent confidence interval of [-0.14 percent; 0.11 percent] and met the prespecified non-inferiority margin (0.4 percent).

    Study B:

    The efficacy of Tresiba was evaluated in a 26-week randomized, open-label, multicenter trial in 455 patients with type 1 diabetes mellitus. Patients were randomized to Tresiba or insulin detemir once-daily in the evening. After 8 weeks, insulin detemir could be dosed twice-daily. Results: 67.1 percent used insulin detemir once daily at end of trial; 32.9 percent used insulin detemir twice daily at end of trial. Insulin aspart was administered before each meal in both treatment arms. At week 26, the difference in HbA1c reduction from baseline between Tresiba and insulin detemir was -0.09 percent with a 95 percent confidence interval of [-0.23 percent; 0.05 percent] and met the prespecified non-inferiority margin (0.4 percent).

    Tresiba administered at the same time each day or at any time each day in combination with a rapid-acting insulin analog at mealtimes:

    Study C:

    The efficacy of Tresiba was evaluated in a 26-week randomized, open-label, multicenter trial in 493 patients with type 1 diabetes mellitus. Patients were randomized to Tresiba injected once-daily at the same time each day (with the main evening meal), to Tresiba injected once daily at any time each day or to insulin glargine U-100 injected once-daily according to the approved labeling. The any time each day Tresiba arm was designed to simulate a worst-case scenario injection schedule of alternating short and long, once daily, dosing intervals (i.e., alternating intervals of eight to 40 hours between doses). Tresiba in this arm was dosed in the morning on Monday, Wednesday and Friday and in the evening on Tuesday, Thursday, Saturday and Sunday. Insulin aspart was administered before each meal in both treatment arms. At week 26, the difference in HbA1c reduction from baseline between Tresiba administered at alternating times and insulin glargine U-100 was 0.17 percent with a 95 percent confidence interval of [0.04 percent; 0.30 percent] and met the pre-specified non-inferiority margin (0.4 percent).

    Type 2 Diabetes

    Tresiba administered at the same time each day as an add-on to metformin with or without a dpp-4 inhibitor in insulin naïve patients:

    Study D:

    The efficacy of Tresiba was evaluated in a 52-week randomized, open-label, multicenter trial that enrolled 1030 insulin naïve patients with type 2 diabetes mellitus inadequately controlled on one or more oral antidiabetic agents (OADs). Patients were randomized to Tresiba once-daily with the evening meal or insulin glargine U-100 once-daily, according to the approved labeling. Metformin alone (82.5 percent) or in combination with a DPP-4 inhibitor (17.5 percent) was used as background therapy in both treatment arms. At week 52, the difference in HbA1c reduction from baseline between Tresiba and insulin glargine U-100 was 0.09 percent with a 95 percent confidence interval of [-0.04 percent; 0.22 percent] and met the prespecified non-inferiority margin (0.4 percent).

    Tresiba U-200 administered at the same time each day as an add-on to metformin with or without a DPP-4 inhibitor in insulin-naïve patients:

    Study E:

    The efficacy of Tresiba U-200 was evaluated in a 26-week randomized, open-label, multicenter trial in 457 insulin naïve patients with type 2 diabetes mellitus inadequately controlled on one or more oral antidiabetic agents (OADs) at baseline. Patients were randomized to Tresiba U-200 once-daily with the evening meal or insulin glargine U-100 once-daily according to the approved labeling. Both treatment arms were receiving metformin alone (84 percent) or in combination with a DPP-4 inhibitor (16 percent) as background therapy. At week 26, the difference in HbA1c reduction from baseline between Tresiba U-200 and insulin glargine U-100 was 0.04 percent with a 95 percent confidence interval of [-0.11 percent; 0.19 percent] and met the pre-specified non-inferiority margin (0.4 percent).

    Tresiba administered at the same time each day in insulin-naïve patients as an add-on to one or more of the following oral agents: metformin, sulfonylurea, glinides or alpha-glucosidase inhibitors:

    Study F:

    The efficacy of Tresiba was evaluated in a 26-week randomized, open-label, multicenter trial in Asia in 435 insulin naïve patients with type 2 diabetes mellitus inadequately controlled on one or more oral antidiabetic agents (OADs) at baseline. Patients were randomized to Tresiba once-daily in the evening or insulin glargine U-100 once-daily according to the approved labeling. Pre-trial oral antidiabetes agents were continued as background therapy except for DPP-4 inhibitors or thiazolidinediones in both treatment arms. At week 26, the difference in HbA1c reduction from baseline between Tresiba and insulin glargine U-100 was 0.11 percent with a 95 percent confidence interval of [-0.03 percent; 0.24 percent] and met the prespecified non-inferiority margin (0.4 percent).

    Tresiba administered at the same time each day or any time each day as an addon to one and up to three of the following oral agents: metformin, sulfonylurea or glinides or pioglitazone:

    Study G:

    The efficacy of Tresiba was evaluated in a 26-week randomized, open-label, multicenter trial in 687 patients with type 2 diabetes mellitus inadequately controlled on basal insulin alone, oral antidiabetic agents (OADs) alone or both basal insulin and OAD. Patients were randomized to Tresiba injected once-daily at the same time each day (with the main evening meal), to Tresiba injected once daily at any time each day or to insulin glargine U-100 injected once-daily according to the approved labeling. The any time each day Tresiba arm was designed to simulate a worst-case scenario injection schedule of alternating short and long, once daily dosing intervals (i.e., alternating intervals of eight to 40 hours between doses). Tresiba in this arm was dosed in the morning on Monday, Wednesday and Friday and in the evening on Tuesday, Thursday, Saturday and Sunday. Up to three of the following oral antidiabetes agents (metformin, sulfonylureas, glinides or thiazolidinediones) were administered as background therapy in both treatment arms. At week 26, the difference in HbA1c reduction from baseline between Tresiba at alternating times and insulin glargine U-100 was 0.04 percent with a 95 percent confidence interval of [-0.12 percent; 0.20 percent]. This comparison met the pre-specified non-inferiority margin (0.4 percent). 

    Tresiba administered at the same time each day in combination with a rapid-acting insulin analog at mealtimes:

    Study H:

    The efficacy of Tresiba was evaluated in a 52-week randomized, open-label, multicenter trial in 992 patients with type 2 diabetes mellitus inadequately controlled on premix insulin, bolus insulin alone, basal insulin alone, oral antidiabetic agents (OADs) alone or any combination thereof. Patients were randomized to Tresiba once-daily with the main evening meal or insulin glargine U-100 once-daily according to the approved labeling. Insulin aspart was administered before each meal in both treatment arms. Up to two of the following oral antidiabetes agents (metformin or pioglitazone) were used as background therapy in both treatment arms. At week 52, the difference in HbA1c reduction from baseline between Tresiba and insulin glargine U-100 was 0.08 percent with a 95 percent confidence interval of [-0.05 percent; 0.21 percent] and met the prespecified non-inferiority margin (0.4 percent).

    TRESIBA administered at any time each day as an add-on to one or two of the following oral agents: metformin, sulfonylurea or pioglitazone:

    Study I:

    The efficacy of Tresiba was evaluated in a 26-week randomized, open-label, multicenter trial in 447 patients with type 2 diabetes mellitus inadequately controlled on one or more oral antidiabetic agent (OADs) at baseline. Patients were randomized to Tresiba once-daily at any time of day or sitagliptin once-daily according to the approved labeling. One or two of the following oral antidiabetes agents (metformin, sulfonylurea or pioglitazone) were also administered in both treatment arms. At the end of 26 weeks, Tresiba provided greater reduction in mean HbA1c compared to sitagliptin (p < 0.001).

     

     

    Approval Date: 2015-09-01
    Company Name: Novo Nordisk
    Back to Listings

    Upcoming Events

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • tablet

      Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

    • Diversity-360x240.png

      Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing